期刊文献+

肥厚梗阻型心肌病化学消融术后早期左心形态重构和电重构

Early left heart shape remodeling and electrical remodelingafter percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy
下载PDF
导出
摘要 目的探讨肥厚梗阻型心肌病(hypertrophic obstructive cardiomyopathy,HOCM)在经皮经冠脉间隔心肌化学消融术(PTSMA)后早期左心几何构型和电生理的变化。方法 32例行PTSMA的HOCM患者,比较术前及术后1个月、6个月经胸超声心动图及心电图测量指标的变化。结果与术前相比,患者术后1个月、6个月时室间隔厚度(IVS)、V1导联P波终末电势(Ptf V1)明显下降;术后6个月左房收缩末期内径(LAD)下降,左室舒张末期内径(LVD)增加,差异均有统计学意义(P<0.05)。术后1个月病理性Q波例数较术前明显增加,差异有统计学意义(P<0.001)。结论 PTSMA是HOCM的有效治疗方法,早期逆转了HOCM患者的心脏重构。 Objective To investigate the early changes of geometric configurations and electrophysiology after percutaneous transluminal septal myocardial ablation( PTSMA) in patients with hypertrophic obstructive cardiomyopathy( HOCM). Methods The PTSMA was performed in 32 patients with HOCM.All patients received echocardiography and electrocardiogram( ECG) examination before operation and after 1 and 6 months of PTSMA.Results In one month and six months after PTSMA,the thickness of interventricular septum( IVS) and p-wave terminal force-v1( Ptf V1) were decreased.In six months after PTSMA,the dimensions of the left atrium( LAD)was reduced while left ventricular( LVD) were increased( P 〈0. 05).the pathologic Q wave were increased significantly after 1 month of operation( P〈 0. 001).Conclusion PTSMA is an effective treatment for patients with HOCM and can reverse cardiac remodeling at the early stage.
出处 《实用医院临床杂志》 2016年第3期70-72,共3页 Practical Journal of Clinical Medicine
基金 四川省卫生厅科研基金资助项目(编号:120538)
关键词 肥厚型心肌病 化学消融 心电图 超声心动图 Hypertrophic cardiomyopathy Chemical ablation Electrocardiogram Echocardiography
  • 相关文献

参考文献9

  • 1Li ZQ, Cheng TO, Zhang WW, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy;The Chinese experience in 119 patients from a single center[J]. Int J Cardio1,2004,93 : 197-202.
  • 2Sigwart U. Non-surgical myocardial reduction for hypertrophic ob- structive cardiomyopathy [J]. Lancet, 1995,346(22) :211-214.
  • 3pelizzon GG, Grines C, Cox DA, et al. Importance of mitral regurgita- tion in patients undergoing percutaneous coronary intervention for a- cute myocardial infarction the Controlled Abciximab and Device In- vestigation to Lower Late Angioplasty Complicalions ( CADILLAC ) tial[J]. J Am Coil Cardiol.2004,43 ( 8 ) : 1368-1374.
  • 4熊峰,唐炯,王淑珍,冯坤,张梅.心肌声学造影在肥厚型梗阻性心肌病无水乙醇化学消融术中的应用[J].临床超声医学杂志,2014,16(11):724-728. 被引量:1
  • 5Sommer A, Poulsen SH, Mogensen J, et al. Left ventricular longitudi- nal systolic function after alcohol septal ablation for hypertrophic ob- structive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography [J]. Eur J Echocardiogr,2010,1 1 (10) :883-888.
  • 6Woo A,Williams WG,Choi R,et al. Clinical and eehoeardiographic de- terminants of long-term survival after surgical myectomy in obstructive hypertrophic eardiomyopathyl- J]. Circulation ,2005,111:2033-2041.
  • 7Jassal DS, Neilan TG, Fifcr MA, et al. Sustained improvement in left ventricular diastolic funetion after alcohol septal ablation for hyper- trophic obstructive cardiomyopathy [J]. Enr Heart J,2006,27 ( 15 ) : 1805-1810.
  • 8关怀敏,解金红,陈玉善,罗明华,王贺,朱明军,胡天勇.肥厚梗阻性心肌病化学消融前后心电图变化及其意义[J].中国心脏起搏与心电生理杂志,2014,28(3):223-226. 被引量:2
  • 9Moon JC, Mckenna WJ, Mcrohan JA, et al. Toward clinical risk as- sessment in hypertrophic cardiomyopathy with gadolinium cardiovas- cular magnetic resonance[J].J Am Coil Cardiol,2003,41:1561.

二级参考文献20

  • 1张鸿丽,张海澄,周北玲,银鹏飞,黄永杰,张萍,郭继鸿.肥厚型心肌病患者心电图分析[J].临床心电学杂志,2007,16(4):253-255. 被引量:4
  • 2Fifer MA, Sigwart U. Hypertrophic obstructive cardiomyopathy, al- cohol septal ablation[J]. Eum heart J,2011,32(9) :1 059.
  • 3Moon JC, Mckenna WJ, Mcrohan JA, et al. Toward clinical risk as- sessment in hypertrophic cardiomyopathy with gadolinium cardiovas- cular magnetic resonance[ J]. J Am Coil Cardiol,2003,41:1 561.
  • 4Rickets C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardio- myopathy [ J ]. Circulation,2005,112 : 855.
  • 5Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventrieular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy [ J ]. Lancet,2001,357:420.
  • 6Prinz C, Farr M, Hering D, et al. The diagnosis and treatment of hypertrophic cardiomyopathy [ J ]. Dtsch Arztebl Int, 2011, 108 (13) : 209.
  • 7van der Lee C,ten Cate FI,Geleijnse ML,et al.Percutaneous versus surgical treatment for patients with hypertrophic ohstructive Cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation, 2005,112(4) : 482-488.
  • 8Bonow RO, Carabello B, Chatterjee K, et al.ACC/AHA2006 guidelines for the management of patients with valvular heart disease: A report of the American Coliege of Cardiology/American Heart Association Task Force Oil Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coil Cardiol, 2006,48 (3) : 1-148.
  • 9Sigwart U.Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.Lancet, 1995,346(22) : 211-214.
  • 10Kimmelstiel CD,Mar on BJ. Role of percutaneous septal ablation in hypertrophic obsructive cardiomyopathy.Circulation, 2004, 109 (2) : 452-456.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部